Commonwealth Biotechnologies, Inc.
(Public, NASDAQ:CBTE) Watch this stockFind more results for
CBTE
Advertisement
Events
Nov 16, 2009
Q3 2009 Commonwealth Biotechnologies Earnings Release
|
More events from AOL Finance »
|
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -24.51% | -90.84% |
| Operating margin | -13.42% | -26.69% |
| EBITD margin | - | -19.31% |
| Return on average assets | -28.09% | -60.34% |
| Return on average equity | -255.51% | -153.11% |
| Employees | 65 | - |
Address
Website links
Company website:
http://www.cbi-biotech.com
http://www.cbi-biotech.com
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Commonwealth Biotechnologies, Inc. discussions
View all discussions »Description
Commonwealth Biotechnologies, Inc. (CBI) is a specialized life sciences outsourcing business that offers a suite of discovery and development services and chemistry and biology products through its subsidiary companies, which include CBI Services, Fairfax Identity Labs (FIL) and Mimotopes Pty Limited (Mimotopes). In April 2008, the Company entered into a joint venture with Beijing-based, VenturePharm Laboratories, Ltd. (VPL) in order to offer high throughput, low cost drug discovery services through facilities in China. As of September 23, 2008, Exelgen Limited (Exelgen) was closed. The Company’s business units include CBI Services, FIL, Mimotopes and VenturePharm joint venture.
Officers and directors
| Bill Guo | Chairman of the Board, Acting Chief Executive Officer | |
| Robert B. Harris Ph.D. | President, Director | |
| Richard J. Freer Ph.D. | Chief Operating Officer, Director | |
| Thomas R. Reynolds | Executive Vice President - Science & Technology | |
| James D. Causey | Director | |
| Paul D'Sylva Ph.D. | Director | |
| Eric Tao | Director | |
| Maria Song M.D., Ph.D. | Director | |
| Samuel P. Sears Jr. | Independent Director |
